Mesoglycan for Pain Control After Open Excisional HAEMOrrhoidectomy

Thrombosis Clinical Trial

— MeHAEMO  

Official title:

Mesoglycan for Pain Control After Open Excisional HAEMOrrhoidectomy (MeHAEMO): An Observational Multicentre Study on Behalf of the Italian Society of Colorectal Surgery (SICCR)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04481698
• Other study ID #: 176/2017
• Status: Completed
• Start date: April 1, 2017
• Est. completion date: December 1, 2017

Study information

• Verified date: July 2020
• Source: Societa Italiana di Chirurgia ColoRettale
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Haemorrhoidal disease (HD) is the most common proctological disease, with a prevalence that can reach up to 39% of the population. Although I and II degree HD can be treated successfully with medical therapy or office-based procedures , excisional haemorrhoidectomy remains the gold standard technique in patients with III and IV degree HD, obtaining a much lower rate of recurrence than non-excisional methods, such as Doppler-guided haemorrhoidal artery ligation or stapled haemorrhoidopexy. However, both open and closed haemorrhoidectomies are associated with a significant rate of post-operative pain , which may be due to the incorporation of sensitive anal mucosa and fibres of the internal sphincters during the ligation of the vascular pedicle, post-operative scars, hygiene/social habits, hard stool, or oedema of the necessary mucocutaneous bridge.

Regarding the oedema/thrombosis of the mucocutaneous bridges, we strongly believe that it is the main cause of post-operative pain, and we have shown that the use of mesoglycan, a polysaccharide complex with antithrombotic and profibrinolytic properties, can reduce the rate of post-operative thrombosis and consequently post-operative pain 7-10 days after the procedures, improving patient quality of life and speeding up the recovery of daily activities.

Furthermore, its usefulness is also evident in the treatment of the acute phase of external haemorrhoidal thrombosis.

The aim of the study was to evaluate the efficacy of mesoglycan in the post-operative period of patients who underwent open excisional diathermy haemorrhoidectomy, confirming the previously obtained results

Description:

This was a retrospective multicentre study and is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for cohort studies

Between September and December 2017, 206 patients with III and IV degree HD, according to Goligher classification, from sixteen colorectal referral centres belonging to SICCR (Società Italiana di Chirurgia Colorettale), who satisfied inclusion criteria underwent open excision haemorrhoidectomy.

The results obtained were compared with a homogeneous sample of 192 patients who underwent OEH in the same centres between April and July 2017 and who had received standard post-operative therapy without mesoglycan.

All patients received the standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners) plus mesoglycan (Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days, Mediolanum Farmaceutici, Milan, Italy).

In each referral centre, the procedures were carried out by an experienced surgeon who had performed more than 200 haemorrhoidectomies.

A clinical external examination was performed the first post-operative day, and an anorectal digital evaluation with proctoscopy was performed at T2, T3 and T4.

During each follow-up visit, post-operative pain was evaluated at rest, after defecation and after anorectal digital examination using a visual analogue scale (minimum score = 0; maximum score = 10).

Quality of life was evaluated pre- and post-operatively 90 days after the procedure using the SF-12 questionnaire.

Polypharmacy was defined as 5 or more medications daily. Thrombosis was defined as one or more swollen painful piles at the site of the mucocutaneous bridge and was assessed at T2, T3 and T4.

Surgical wound healing (granulation) was evaluated at T2, T3 and T4 using the following 3 items: infected, granulating, healed.

Autonomy was evaluated at T2, T3 and T4 using the following 4 items: complete inactivity, total autonomy at home, ability to drive, return to normal activities (autonomy at home, driving, working).

Bowel movements were evaluated, according to the proper guidelines, at T2, T3 and T4, and patients were classified in three categories: regular, constipation or diarrhoea.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 398
• Est. completion date: December 1, 2017
• Est. primary completion date: December 1, 2017
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• III and IV degree Hemorrhoidal Disease

• Age > 18

• Written Informed Consent

Exclusion Criteria:

• Age <18

• Past or present history of:

• Coagulopathy

• Cardiac Diseases

• Anticoagulant Therapies

• Colorectal or Anal Neoplasms

• Inflammatory Bowel Disease

• Pelvic Radiotherapy

• Anal Surgery

• Allergy to Mesoglycan

• Inability to return for post-operative control visits

Related Conditions & MeSH terms

• Haemorrhoidal Disease
• Pain, Postoperative
• Post-operative Pain
• Thrombosis

Intervention

Other:
• Mesoglycan
Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days

Locations

Country	Name	City	State
Italy	University of Catanzaro	Catanzaro

Sponsors (8)

Lead Sponsor	Collaborator
Societa Italiana di Chirurgia ColoRettale	Alberto Realis Luc, Alessandro Sturiale, Gaetano Gallo, Giuseppe Clerico, Giuseppe Sammarco, Mario Trompetto, Michele Manigrasso

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Bessa SS. Diathermy excisional hemorrhoidectomy: a prospective randomized study comparing pedicle ligation and pedicle coagulation. Dis Colon Rectum. 2011 Nov;54(11):1405-11. doi: 10.1097/DCR.0b013e318222b5a9. — View Citation

Cocorullo G, Tutino R, Falco N, Licari L, Orlando G, Fontana T, Raspanti C, Salamone G, Scerrino G, Gallo G, Trompetto M, Gulotta G. The non-surgical management for hemorrhoidal disease. A systematic review. G Chir. 2017 Jan-Feb;38(1):5-14. — View Citation

Gallo G, Martellucci J, Sturiale A, Clerico G, Milito G, Marino F, Cocorullo G, Giordano P, Mistrangelo M, Trompetto M. Consensus statement of the Italian society of colorectal surgery (SICCR): management and treatment of hemorrhoidal disease. Tech Colopr — View Citation

Gallo G, Mistrangelo M, Passera R, Testa V, Pozzo M, Perinotti R, Lanati I, Lazzari I, Tonello P, Ugliono E, De Luca E, Realis Luc A, Clerico G, Trompetto M. Efficacy of Mesoglycan in Pain Control after Excisional Hemorrhoidectomy: A Pilot Comparative Pro — View Citation

Simillis C, Thoukididou SN, Slesser AA, Rasheed S, Tan E, Tekkis PP. Systematic review and network meta-analysis comparing clinical outcomes and effectiveness of surgical treatments for haemorrhoids. Br J Surg. 2015 Dec;102(13):1603-18. doi: 10.1002/bjs.9 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Post-operative Pain	VAS	Day 7, Day 20, Day 40
Secondary	Changes in post-operative Thrombosis	Dichotomous parameter (Yes or Not)	Day 7, Day 20, Day 40
Secondary	Changes in post-operative Bleeding	Dichotomous parameter (Yes or Not)	Day 7, Day 20, Day 40
Secondary	Quality of Life (QoL)	We used the 12-Item Short Form Survey (SF-12) to assess QoL	pre- and post-operatively 90 days after the procedure
Secondary	Changes in Surgical Wound Healing	we evaluated wound healing with the following scale: infected, granulating, healed	Day 7, Day 20, Day 40
Secondary	Changes Autonomy	we evaluated autonomy with the following parameters: complete inactivity (patient unable to performing any activity), total autonomy at home, ability to drive, return to normal activities (patient able to performing any activity)	Day 7, Day 20, Day 40